The real-world study presented at WCO-IOF-ESCEO 2023 evaluating Prolia vs alendronate from 478,651 postmenopausal women aged ≥66yrs. The retrospective analysis was based on a US Medicare beneficiary database
The results showed a 36% & 43% reduction in risk of hip fractures & nonvertebral fractures, 30% in the risk of hospitalized vertebral fractures, 39% in the risk of major osteoporotic, nonvertebral & hospitalized vertebral fractures, 50% reduced risk of non-hip, nonvertebral fractures
The analysis also showed that a longer duration of treatment with denosumab led to a greater reduction in risk of major osteoporotic fracture at 1/2/3/5yr. were 9%/12%/18%/31% and 39% overall, respectively
Ref: PRNewswire | Image: Amgen
Related News:- AryoGen Pharmed Reports P-III Trial Results of Denosumab Biosimilar Demonstrates Noninferiority to Prolia for Postmenopausal Osteoporosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
